Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Dividends per Share : $0.00 (TTM As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Dividends per Share?

Cotinga Pharmaceuticals's dividends per share for the three months ended in Jan. 2020 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Jan. 2020 was $0.00. Its Dividend Payout Ratio for the three months ended in Jan. 2020 was 0.00. As of today, Cotinga Pharmaceuticals's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Cotinga Pharmaceuticals Dividends per Share Historical Data

The historical data trend for Cotinga Pharmaceuticals's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Dividends per Share Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Dividends per Share

Get a 7-Day Free Trial

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cotinga Pharmaceuticals's Dividends per Share

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cotinga Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Dividend Yield % falls into.

Cotinga Pharmaceuticals Dividends per Share Calculation

Dividends paid to per common share.

Cotinga Pharmaceuticals (OTCPK:COTQF) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Cotinga Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Jan. 2020 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jan. 2020 )	/	EPS without NRI (Q: Jan. 2020 )
	=	0	/	-0.015
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Cotinga Pharmaceuticals Dividends per Share Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019